Kangxinuo (688185.SH): Approval obtained for clinical trial of restructuring trivalent polio vaccine (Sf-RVN cells)

Smart Finance APP News, Kangxinuo (688185.SH) announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration regarding the restructuring of the trivalent polio vaccine (Sf-RVN cells), agreeing to conduct clinical trials for the prevention of poliomyelitis caused by type I, II, and III poliovirus infections.